Top Stories
- FDA licenses and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants
- FDA changes schedule for GSK MenB (Bexsero): now same schedule as Pfizer MenB (Trumenba) with 2 doses 6 months apart or 3 doses given at 0, 1–2, and 6 months
- Immunize.org updates “Ask the Experts: Influenza” web section for the 2024–25 influenza season
- Immunize.org adds new PCV21 to “Ask the Experts: Pneumococcal” web section
- “National Vaccination Coverage among Adolescents Aged 13–17 Years—National Immunization Survey-Teen, United States, 2023” published in MMWR
- “Human Papillomavirus Vaccination Coverage among Adolescent Girls Aged 13–17 Years—U.S.-Affiliated Pacific Islands, 2013–2023” published in MMWR
- Immunize.org adds new vaccines to popular resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!”
- Immunize.org updates “Vaccines with Diluents: How to Use Them” resource
- Watch and share the latest installment in Immunize.org’s Orientation Video Series: Introducing VIS and VIS Translations
- Journalists interview Immunize.org experts
- Vaccines in the news
Immunize.org Website and Clinical Resources
- Spotlight on the website: This season’s influenza VISs and access to translations
- Recap: Immunize.org introduces standing orders template for RSV vaccination of adults age 60 years and older
- Recap: Immunize.org updates the screening checklists for contraindications to injectable and live attenuated influenza vaccines for the 2024–25 season
- Recap: Immunize.org updates “Administering Vaccines: Dose, Route, Site, and Needle Size” and companion version for adults
- Recap: Immunize.org updates “Notification of Immunization Letter Template” to include newly recommended vaccines